AU2012340712B2 - Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response - Google Patents

Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response Download PDF

Info

Publication number
AU2012340712B2
AU2012340712B2 AU2012340712A AU2012340712A AU2012340712B2 AU 2012340712 B2 AU2012340712 B2 AU 2012340712B2 AU 2012340712 A AU2012340712 A AU 2012340712A AU 2012340712 A AU2012340712 A AU 2012340712A AU 2012340712 B2 AU2012340712 B2 AU 2012340712B2
Authority
AU
Australia
Prior art keywords
seq
polypeptide
hsv
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012340712A
Other languages
English (en)
Other versions
AU2012340712A1 (en
Inventor
Jessica Flechtner
Deborah Long
Mojca Skoberne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genocea Biosciences Inc
Original Assignee
Genocea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genocea Biosciences Inc filed Critical Genocea Biosciences Inc
Publication of AU2012340712A1 publication Critical patent/AU2012340712A1/en
Application granted granted Critical
Publication of AU2012340712B2 publication Critical patent/AU2012340712B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012340712A 2011-11-23 2012-11-21 Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response Ceased AU2012340712B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563507P 2011-11-23 2011-11-23
US61/563,507 2011-11-23
PCT/US2012/066241 WO2013078299A1 (en) 2011-11-23 2012-11-21 Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Publications (2)

Publication Number Publication Date
AU2012340712A1 AU2012340712A1 (en) 2014-06-12
AU2012340712B2 true AU2012340712B2 (en) 2017-09-14

Family

ID=48470287

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012340712A Ceased AU2012340712B2 (en) 2011-11-23 2012-11-21 Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response

Country Status (6)

Country Link
US (1) US9624273B2 (enExample)
EP (1) EP2782597B1 (enExample)
JP (1) JP6199878B2 (enExample)
AU (1) AU2012340712B2 (enExample)
CA (1) CA2885693C (enExample)
WO (1) WO2013078299A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458463B (zh) 2009-05-22 2017-01-18 健诺西生物科学公司 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法
CA2856697A1 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
US10350288B2 (en) * 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016779A1 (en) * 1993-12-14 1995-06-22 Smithkline Beecham Biologicals (S.A.) Herpes-symplex-virus type 2 icp4 protein and its use in a vaccine composition
US20030165819A1 (en) * 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2003086308A2 (en) * 2002-04-11 2003-10-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20100330112A1 (en) * 2009-05-22 2010-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
NZ209308A (en) 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5612041A (en) 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5149529A (en) 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
EP0471778A1 (en) 1989-05-12 1992-02-26 Ciba Corning Diagnostics Corp. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
CA2088600C (en) 1990-08-02 1999-11-16 Rae L. Burke Herpes simplex virus vp16 vaccines
DK31991D0 (da) 1991-02-25 1991-02-25 Carlbiotech Ltd As Peptid og farmaceutisk praeparat indeholdende et saadant peptid
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5679348A (en) * 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US5955088A (en) * 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
CA2164601A1 (en) 1993-06-08 1994-12-22 Kevin R. Steffy Herpes simplex virus type-2 protease
MXPA94006367A (es) 1993-08-20 2004-09-09 Smithkline Beecham Corp Gene novedoso.
US7094767B2 (en) 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US5807557A (en) * 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6197497B1 (en) 1995-04-21 2001-03-06 University Of New Mexico Immunoassay for herpes simplex virus
US5654174A (en) 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US5876923A (en) * 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
JP2002514056A (ja) 1996-10-23 2002-05-14 アメリカン・ホーム・プロダクツ・コーポレーション ワクチン
EP0948508A4 (en) 1996-11-04 2001-11-07 Smithkline Beecham Corp NEW CODING SEQUENCES FOR HERPES SIMPLEX TYPE 2 VIRUS
EP0984790A1 (en) 1997-06-02 2000-03-15 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6054131A (en) 1998-01-16 2000-04-25 University Of Maryland Baltimore Vaccine composition for herpes simplex virus and method of using
DE69933200T2 (de) 1998-03-09 2007-02-22 Glaxosmithkline Biologicals S.A. Kombinierte impfstoffzusammensetzungen
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
IL141044A0 (en) 1998-08-07 2002-02-10 Univ Washington Innunological herpes simplex virus antigens and methods for use thereof
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
PL210451B1 (pl) 1999-06-10 2012-01-31 Merial Sas Szczepionka DNA przeciwko wirusowi nosówki psów (CDV)
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
AU782676B2 (en) 1999-09-30 2005-08-18 Corixa Corporation Immunologically significant herpes simplex virus antigens
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
ATE319833T1 (de) * 1999-12-17 2006-03-15 Wyeth Corp Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
WO2002002131A2 (en) 2000-06-29 2002-01-10 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
ATE381351T1 (de) 2000-07-27 2008-01-15 Univ Pennsylvania Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
EP1178111A1 (en) * 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
JP2005510489A (ja) 2000-11-16 2005-04-21 ユニバーシティ オブ メリーランド，ボルチモア 再発性のウイルス性疾患の予防
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
AU2002367976B2 (en) 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
WO2003011893A2 (en) 2001-07-31 2003-02-13 University Of Washington Immunologically significant herpes simplex virus antigens and methods for using same
AU2002323443A1 (en) 2001-09-04 2003-03-18 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030219448A1 (en) 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
US20080299140A1 (en) 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
AU2003252052A1 (en) 2002-07-18 2004-02-09 University Of Washington Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
US7267940B2 (en) 2003-03-04 2007-09-11 Bio-Rad Laboratories, Inc. HSV-2 type-specific immunoassays using glycoprotein G2 peptides
EP2289547B1 (en) 2003-09-12 2015-12-16 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
CA2630218A1 (en) 2005-11-18 2007-08-30 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
EP2001516A4 (en) 2006-03-10 2010-04-28 Univ California VACCINATES AGAINST PERSISTENT OR LATENT INFECTIONS THREADING VIRUSES
CA2658484A1 (en) 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
US20090246220A1 (en) 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
CN101583381B (zh) 2006-09-08 2014-05-07 宾夕法尼亚大学董事会 Hsv-1和hsv-2疫苗和其使用方法
EP2087128A4 (en) 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
AU2007342345B9 (en) 2006-12-28 2013-09-12 The Trustees Of The University Of Pennsylvania Herpes Simplex Virus combined subunit vaccines and methods of use thereof
US7785605B2 (en) 2007-07-05 2010-08-31 University Of Kansas Herpes simplex virus mutant ICP0 protein
WO2009006680A1 (en) 2007-07-06 2009-01-15 Sydney West Area Health Service Epitopes of herpes simplex virus
SE532551C2 (sv) 2008-06-30 2010-02-16 Senseair Ab Ett för spektralanalys anpassat arrangemang
AU2009266924B2 (en) * 2008-07-01 2015-12-10 Genocea Biosciences, Inc. Antigen screening system
EP2379106A4 (en) * 2008-12-17 2012-06-13 Genocea Biosciences Inc ANTIGENS OF CHLAMYDIAS AND USES THEREOF
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
US9089537B2 (en) * 2010-02-26 2015-07-28 The Trustees Of The University Of Pennslyvania Subunit vaccines for herpes viruses and methods of use
CA2792679C (en) * 2010-03-09 2019-11-12 Mucosal Vaccine Thechnologies Llc A novel mucosal vaccination approach for herpes simplex virus type-2
CA2849391A1 (en) * 2010-10-20 2012-04-26 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
CA2856697A1 (en) * 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016779A1 (en) * 1993-12-14 1995-06-22 Smithkline Beecham Biologicals (S.A.) Herpes-symplex-virus type 2 icp4 protein and its use in a vaccine composition
US20030165819A1 (en) * 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2003086308A2 (en) * 2002-04-11 2003-10-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20100330112A1 (en) * 2009-05-22 2010-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRAUN R. P. et al. Multi-antigenic DNA immunization using herpes simplex virus type 2 genomic fragments, HUMAN VACCINES, 2008, vol. 4, no. 1, pages 36-43 *

Also Published As

Publication number Publication date
JP6199878B2 (ja) 2017-09-20
WO2013078299A1 (en) 2013-05-30
US9624273B2 (en) 2017-04-18
CA2885693A1 (en) 2013-05-30
EP2782597A4 (en) 2015-11-11
EP2782597B1 (en) 2022-04-13
US20140328870A1 (en) 2014-11-06
CA2885693C (en) 2020-07-28
EP2782597A1 (en) 2014-10-01
JP2014534262A (ja) 2014-12-18
AU2012340712A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
US10653771B2 (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
AU2011336894B2 (en) Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
US10350288B2 (en) Methods and compositions for treating herpes
US9624273B2 (en) Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired